| Lupus Nephritis

Benlysta vs Gazyva

Side-by-side clinical, coverage, and cost comparison for lupus nephritis.

Deep comparison between: Benlysta vs Gazyva with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsGazyva has a higher rate of injection site reactions vs Benlysta based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Gazyva but not Benlysta, including UnitedHealthcare

Category

Benlysta

Gazyva

At A Glance

RouteIV infusion or SC injection

FrequencyWeekly or every 4 weeks

ClassBLyS inhibitor

RouteIV infusion

ClassAnti-CD20 monoclonal antibody

Indications

Lupus Erythematosus, Systemic
Lupus Nephritis

Chronic Lymphocytic Leukemia
Lymphoma, Follicular
Lupus Nephritis

Dosing

Lupus Erythematosus, Systemic IV: 10 mg/kg at 2-week intervals for first 3 doses then every 4 weeks as a 1-hour infusion; SC adults and pediatric >=40 kg: 200 mg once weekly; SC pediatric 15 to <40 kg: 200 mg once every 2 weeks.

Lupus Nephritis IV: 10 mg/kg at 2-week intervals for first 3 doses then every 4 weeks as a 1-hour infusion; SC adults and pediatric >=40 kg: 400 mg once weekly for 4 doses then 200 mg once weekly; SC pediatric 15 to <40 kg: 200 mg once weekly for 4 doses then 200 mg once every 2 weeks.

Chronic Lymphocytic Leukemia 100 mg IV on day 1 and 900 mg on day 2 of Cycle 1, then 1,000 mg on days 8 and 15 of Cycle 1, and 1,000 mg on day 1 of Cycles 2-6 (28-day cycles) in combination with chlorambucil.

Lymphoma, Follicular 1,000 mg IV on days 1, 8, and 15 of Cycle 1, then 1,000 mg on day 1 of Cycles 2-6 or 2-8 in combination with chemotherapy; responding patients continue on 1,000 mg monotherapy every 2 months for up to 2 years.

Lupus Nephritis 1,000 mg IV at initial infusion (Dose 1), at Week 2 (Dose 2), at Week 24 (Dose 3), at Week 26 (Dose 4), then 1,000 mg every 6 months thereafter, in combination with standard therapy.

Contraindications

Previous anaphylaxis with belimumab

Known hypersensitivity reaction (e.g., anaphylaxis) to obinutuzumab or any excipient
Serum sickness with prior obinutuzumab use

Drug Interactions

379View drug interactions

616View drug interactions

Adverse Reactions

Most common (>=3%) Nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, cystitis, leukopenia, gastroenteritis viral

Serious Serious infections, hypersensitivity reactions including anaphylaxis, depression and suicidality, malignancy

Postmarketing Fatal anaphylaxis

Most common (>=10%) Infusion-related reactions, neutropenia, thrombocytopenia, diarrhea, fatigue, upper respiratory tract infection, musculoskeletal pain

Serious Hepatitis B virus reactivation, progressive multifocal leukoencephalopathy, infusion-related reactions, hypersensitivity reactions including serum sickness, tumor lysis syndrome, infections, neutropenia, thrombocytopenia, disseminated intravascular coagulation

Postmarketing Serum sickness

Pharmacology

BENLYSTA is a BLyS-specific inhibitor; a human IgG1lambda monoclonal antibody that blocks binding of soluble BLyS, a B-cell survival factor, to its receptors on B cells, thereby inhibiting survival of B cells including autoreactive B cells and reducing their differentiation into immunoglobulin-producing plasma cells.

Obinutuzumab is a humanized anti-CD20 IgG1 monoclonal antibody with reduced fucose content that mediates B-cell lysis via immune effector cell engagement (ADCC and ADCP), direct intracellular death signaling, and complement activation; its reduced fucose content confers greater ADCC activity than rituximab.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Benlysta